Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)

The European Patent Office has granted Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), a new patent. This patent covers methods for preventing and treating diarrhea associated with congenital diarrheal disorders (CDDs) using crofelemer, a plant-based prescription drug.

This marks a significant milestone for Jaguar Health, which now holds approximately 200 patents issued and pending. The company is currently backing proof-of-concept studies for crofelemer aimed at treating short bowel syndrome (SBS) and microvillus inclusion disease (MVID). Results from these studies are anticipated by the end of 2024 and throughout 2025.

MVID is a severe infantile condition characterized by chronic diarrhea and malabsorption, with no approved drug treatments available. SBS patients often suffer from intestinal failure, necessitating costly parenteral nutrition and facing significant health risks.

Crofelemer is derived from the Croton lechleri tree in the Amazon Rainforest and is recognized for its unique benefits. The new patent enhances the intellectual property protection around this innovative drug as Jaguar Health expands its reach in Europe and other regions.